secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2026-06-16T20:06:06+00:00
Accession:  0001437749-26-020793
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Puma shareholders reject CEO Auerbach's warrant extension to Oct 2028
---------------------------------------------------------------------

- All 8 director nominees elected; KPMG ratified as auditor for fiscal 2026.
- Advisory say-on-pay approved: 29.3M for, 7.9M against, 0.7M abstain.
- Warrant amendment defeated: 18.2M for, 19.6M against, 0.09M abstain.
- CEO Auerbach's warrant expires Oct 4, 2026; exercisable at $16 for 2.1M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/0001437749-26-020793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926020793/pbyi20260613_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-020793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer